How much is Teva paying, and over what timeframe?
Teva's major settlements run to the end of the decade: $225 million over five years on the criminal case, $450 million over six years for Copaxone, and opioid payments of roughly $364–$418 million per year through 2027 — all structured around its ability to pay.
Teva's major settlements are paid in instalments stretching to the end of the decade. Under the criminal deferred prosecution agreement, it pays $225 million in $22.5 million instalments each year from 2024 to 2027 and $135 million in 2028. The $425 million Copaxone settlement is paid over six years: $19 million in late 2024, $34 million in 2025, $49 million in each of 2026 and 2027, $99 million in 2028 and $175 million in 2029.
The Justice Department said that $450 million total was set according to Teva's ability to pay, based on its financial statements. Opioid settlement payments were estimated at $424 million in 2023 and roughly $364 million to $418 million a year through 2027, with further payments beyond 2028. Critics argue that ability-to-pay reductions mean penalties are smaller than the harm alleged; Teva says the settlements let it move forward.